A novel therapeutic that has been shown in advanced pre-clinical studies to target cancer without the toxic side effects of treatments like chemotherapy has earned the Gunning Group the top prize in a new business pitch competition. Established to reward and accelerate U of T’s innovative technologies and start-ups, the RBC Prize for Innovation and Entrepreneurship was presented to Dalriada Therapeutics, a company co-founded by Professor Gunning. He and his team plan to use t